OncoMatch/Clinical Trials/NCT04054167
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Is NCT04054167 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Low Dose Radiation Therapy for recurrent mantle cell lymphoma.
Treatment: Low Dose Radiation Therapy — This phase II trial studies how well ultra low dose radiation works before or after chemotherapy-free targeted therapy in treating patients with mantle cell lymphoma that has come back or does not respond to treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Ultra low dose radiation is generally associated with a lower risk of side effects which may allow patients to be able to receive low-dose radiation therapy more often than high-dose radiation therapy. This trial may help doctors learn if giving ultra low dose radiation helps control mantle cell lymphoma and improves response to chemotherapy free targeted therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: unless additional radiation therapy is considered safe by the treating radiation oncologist
Has had prior radiation therapy to the potential radiation target such that additional radiation therapy is considered unsafe by the treating radiation oncologist
Lab requirements
Blood counts
platelet count >25,000/mm3 and absolute neutrophil count (ANC) > 1,000/mm3; patients with bone marrow infiltration by MCL are eligible if their ANC is ≥ 1000/mm3 [growth factor not allowed] or their platelet level is ≥ 25,000/mm3
Kidney function
Cr Clearance ≥ 30 mL/min
Liver function
Serum bilirubin <1.5 mg/dl; AST (SGOT) and ALT (SGPT) < 3 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present
Serum bilirubin <1.5 mg/dl and Cr Clearance ≥ 30 mL/min, platelet count >25,000/mm3 and absolute neutrophil count (ANC) > 1,000/mm3, AST (SGOT) and ALT (SGPT) < 3 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present. Patients who have bone marrow infiltration by MCL are eligible if their ANC is ≥ 1000/mm3 [growth factor not allowed] or their platelet level is ≥ 25,000/mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify